Related Experiment Video
Updated: Aug 8, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
SARS-CoV-2 dilated cardiomyopathy
Manuel Felipe Cáceres-Acosta1, Bairon Díaz Idrobo2, Diana Carolina Urbano Albán2
1Cardiologist, Cardiovascular Line of the Health Research Group (GIS) and Postgraduate Professor, University of Cauca Hospital Universitario San José, Carrera 6 #10N-142, 190002 Popayán, Cauca, Colombia.
Abstract:
SARS-CoV-2 is an emerging cause of viral myocarditis that generates multiple complications, such as dilated cardiomyopathy. We describe a young, obese male patient with severe myocardial involvement by the SARS-CoV-2 virus, who presented with chest pain, elevated cardiac enzymes, non-specific electrocardiographic findings, echocardiogram with evidence of dilated heart disease with reduced ejection fraction, and subsequent verification using magnetic resonance imaging (MRI). The results of the cardiac MRI were typical of viral myocarditis. The patient did not respond to a short course of systemic steroids and the standard management for heart failure, had multiple re-admissions, and, unfortunately, died.
More Related Videos
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Myocarditis I: Introduction
Cardiomyopathy V: Interprofessional Care

